Week in Review: CITIC Offers $3.6 Billion to Acquire China Biologic

Deals and Financings   CITIC Capital has submitted a $3.6 billion bid to acquire China Biologic Products, one of China 's five largest plasma-based biopharmas; CSL Limited of Australia will pay $102 million to buy 20% of RuiDe Biological. a China plasma company; one year ago it paid $352 million for an 80% stake in RuiDe; Stealth Biotherapeutics, a Boston a company focusing on mitochondrial dysfunction, completed a $100 million financing led by Nan Fung Technology; Alpha Biopharma of Shanghai closed the first $37 million tranche of a $65 million Series A financing led by Qiming Venture Partners; Shanghai 's Nuance Biotech in-licensed China rights to a non-opioid treatment for long-lasting pain from US-based Pacira Pharma in a $58 million deal; WindMIL Therapeutics of Baltimore, an IO company, closed a $32.5 million B financing led by the US arm of China 's Qiming Venture Partners; WuXi Biologics began construction of a $20 million biologics conjugate drug R&D/CDMO center in Wuxi city; California 's Los Altos Pharma in-licensed greater China rights to a pain product from Sedor Pharma of Pennsylvania ; Trials and Approvals   CStone Pharma of Suzhou dosed the first patient in an Australian Phase I trial of CS3006, a MEK inhibitor; Yantai's Luye Pharma said the CFDA accepted its IND filing for a China Class 1.1 novel analgesia candidate; Company News   CASI Pharma reached an agreement with Shijiazhuang Yiling Pharma to manufacture two generic drugs, entecavir and cilostazol, for China use; Tot Biopharm, a Suzhou oncology company, completed a monoclonal antibodies (mAb) manufacturing facility, for itself and other pharmas on a CDMO basis; Industry Insights   Dr. Jonathan Wang, Senior Managing Director of OrbiMed Asia, told ChinaBio® Today  that China 's biopharma sector is "a once-in-a-lifetime opportunity," though probably a bubble at the moment, which Dr. Wang sees as ending in a correction, not a crash, because the fundamentals of China's underlying market and support system remain strong. Stock Symbols: (NSDQ: CBPO) (ASX: CSL; USOTC: CSLLY) (NSDQ: PCRX) (HK: 2269) (HK: 2186) (NSDQ: CASI) Share this with colleagues: // //